DecImmune Therapeutics Garners $2,250,000 Series A Financing Round

  • Feed Type
  • Date
    1/17/2013
  • Company Name
    DecImmune Therapeutics
  • Mailing Address
    800 Huntington Ave. Boston, MA 02115
  • Company Description
    The company operates as a drug development company focused on inflammation.
  • Website
    http://www.decimmune.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $2,250,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funding announced today will support preclinical development of DecImmune’s therapeutic program targeting heart failure as an adjunct to current standards of care. Heart attack remains the leading cause of death in the United States, responsible for 1.2 million deaths per year.
  • M&A Terms
  • Venture Investor
    Broadview Ventures
  • Venture Investor
    Astellas Venture Capital
  • Venture Investor
    HealthCare Ventures